Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium

Journal of Clinical Investigation

Volumn 123, Issue 6, 2013, Pages 2590-2603

  Van Hauwermeiren, Filip ^a   Armaka, Marietta ^b   Karagianni, Niki ^b,c   Kranidioti, Ksanthi ^b   Vandenbroucke, Roosmarijn E ^a   Loges, Sonja ^d,e,g   Van Roy, Maarten ^a   Staelens, Jan ^a,d   Puimège, Leen ^a   Palagani, Ajay ^f   Vanden Berghe, Wim ^f   Victoratos, Panayiotis ^b   Carmeliet, Peter ^d,e   Libert, Claude ^a   Kollias, George ^b  

^a GHENT UNIVERSITY   (Belgium)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c Biomedcode Hellas SA   (Greece)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; I KAPPA B; INTERLEUKIN 12P40; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P55 TUMOR NECROSIS FACTOR RECEPTOR FAB FRAGMENT; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PREVENTION; CANCER REGRESSION; CANCER THERAPY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; IN VIVO STUDY; INFLAMMATION; INTESTINE EPITHELIUM; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYTOKINES; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIUM; GENE EXPRESSION; GENE KNOCK-IN TECHNIQUES; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTESTINAL MUCOSA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878589884     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65624     Document Type: Article

References (49)

1. Brouckaert PG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W. In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-γ, on a syngeneic murine melanoma. Int J Cancer. 1986;38(5):763-769.
2. Tracey KJ, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234(4775):470-474.
3. Wielockx B, et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med. 2001;7(11):1202-1208.
4. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361-371.
5. Lejeune F, et al. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. J Infus Chemother. 1995;5(2):73-81.
6. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10(1):52-60.
7. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol. 1998;10(5):573-580.
8. Grunhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM. Technology insight: Utility of TNFalpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol. 2006;3(2):94-103.
9. Hundsberger H, et al. TNF: a moonlighting protein at the interface between cancer and infection. Front Biosci. 2008;13:5374-5386.
10. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5(10):392-399.
11. Stoelcker B, et al. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol. 2000;156(4):1171-1176.
12. Rothe J, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993; 364(6440):798-802.
13. Peschon JJ, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 1998;160(2):943-952.
14. Pfeffer K, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73(3):457-467.
15. Ameloot P, et al. Bioavailability of recombinant tumor necrosis factor determines its lethality in mice. Eur J Immunol. 2002;32(10):2759-2765.
16. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev. 1999;169:175-194.
17. Van Antwerp DJ, Martin SJ, Verma IM, Green DR. Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol. 1998;8(3):107-111.
18. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114(2):181-190.
19. Lejeune FJ, Ruegg C. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Bull Cancer. 2006;93(8):E90-E100.
20. Ruegg C, et al. Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat Med. 1998;4(4):408-414.
21. Duprez L, et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity. 2012;35(6):908-918.
22. Libert C, Van Bladel S, Brouckaert P, Fiers W. The influence of modulating substances on tumor necrosis factor and interleukin-6 levels after injection of murine tumor necrosis factor or lipopolysaccharide in mice. J Immunother. 1991; 10(4):227-235.
23. Kettelhut IC, Fiers W, Goldberg AL. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci U S A. 1987;84(12):4273-4277.
24. Takahashi N, et al. IL-17 produced by Paneth cells drives TNF-induced shock. J Exp Med. 2008;205(8):1755-1761.
25. Everaerdt B, Brouckaert P, Fiers W. Recombinant IL-1 receptor antagonist protects against TNF-induced lethality in mice. J Immunol. 1994;152(10):5041- 5049.
26. Kilbourn RG, et al. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci U S A. 1990;87(9):3629-3632.
27. Huys L, et al. Type I interferon drives tumor necrosis factor-induced lethal shock. J Exp Med. 2009;206(9):1873-1882.
28. Cauwels A, Rogge E, Janssen B, Brouckaert P. Reactive oxygen species and small-conductance calcium-dependent potassium channels are key mediators of inflammation-induced hypotension and shock. J Mol Med (Berl). 2010;88(9):921-930.
29. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411-452.
30. Piguet PF, Vesin C, Guo J, Donati Y, Barazzone C. TNF-induced enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does not require p53. Eur J Immunol. 1998;28(11):3499-3505.
31. Vereecke L, et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med. 2010;207(7):1513-1523.
32. Guma M, et al. Constitutive intestinal NF-κB does not trigger destructive inflammation unless accompanied by MAPK activation. J Exp Med. 2011;208(9):1889-1900.
33. Lewis M, et al. Cloning and expression of cDNAs for 2 distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A. 1991;88(7):2830-2834.
34. Le Hir M, et al. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J Exp Med. 1996;183(5):2367-2372.
35. Victoratos P, et al. FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses. Immunity. 2006;24(1):65-77.
36. Roulis M, Armaka M, Manoloukos M, Apostolaki M, Kollias G. Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc Natl Acad Sci U S A. 2011;108(13):5396-5401.
37. Gibson PR. Increased gut permeability in Crohn's disease: is TNF the link? Gut. 2004;53(12):1724-1725.
38. Van Molle W, Libert C, Fiers W, Brouckaert P. Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. J Immunol. 1997;159(7):3555-3564.
39. Cauwels A, et al. Involvement of IFN-gamma in Bacillus Calmette-Guerin-induced but not in tumor-induced sensitization to TNF-induced lethality. J Immunol. 1995;154(6):2753-2763.
40. Carswell EA, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72(9):3666-3670.
41. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986;320(6063):584-588.
42. Smith JW 2nd, et al. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma. J Immunother. 1991;10(5):355-362.
43. Cauwels A, Brouckaert P. Survival of TNF toxicity: dependence on caspases and NO. Arch Biochem Biophys. 2007;462(2):132-139.
44. Schwabe RF, Brenner DA. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol. 2006;290(4):G583-G589.
45. Brenchley JM, Douek DC. Microbial translocation across the GI tract (*). Annu Rev Immunol. 2012; 30:149-173.
46. Xanthoulea S, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med. 2004;200(3):367-376.
47. Armaka M, et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008;205(2):331-337.
48. Van Snick J, et al. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A. 1986;83(24):9679-9683.
49. Vandesompele J, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.